Active Ingredients

Rivaroxaban 2.5, 10, 15, 20mg


Vaxato is a factor Xa inhibitor indicated:

• to reduce risk of stroke and systemic embolism in nonvalvular atrial fibrillation

• for treatment of deep vein thrombosis (DVT)

• for treatment of pulmonary embolism (PE)

• for reduction in the risk of recurrence of DVT or PE

• for the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery

• for prophylaxis of venous thromboembolism (VTE) in acutely ill medical patients

• to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD)

• to reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients after recent lower extremity revascularization due to symptomatic PAD.

• For the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers, co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine.

Mechanism of Action

Vaxato is a highly selective direct factor Xa inhibitor with oral bioavailability. Inhibition of factor Xa interrupts the intrinsic and extrinsic pathway of the blood coagulation cascade, inhibiting both thrombin formation and development of thrombi. Rivaroxaban has no direct effect on platelet aggregation, but indirectly inhibits platelet aggregation induced by thrombin. By inhibiting FXa, rivaroxaban decreases thrombin generation.

Package and Storage

Vaxato® 2.5,10,15, 20mg each contains 30 tablets

Store below 30°C in a dry place